A meta-analysis found that overall survival in PUC was worse than in conventional urothelial carcinoma with borderline significance after adjusting for other clinicopathological characteristics ( 3 ).
← all excerpts
Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma.
1
—
—